Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genticel Appoints New Vice-President

Published: Friday, November 08, 2013
Last Updated: Friday, November 08, 2013
Bookmark and Share
Appointment of Dr Gerald Moeller as vice-president of Company’s supervisory board.

Genticel has appointed a new vice-president to the supervisory board.

Dr Gerald Moeller, PhD has over 35 years experience in the pharmaceutical and diagnostics industry. He has been an investment adviser at HBM Partners in Switzerland since 2002 and chairs the supervisory boards of a number of health sector companies, including 4Sigma Ltd, Definiens AG, Invendo-Medical GmbH and MorphoSys AG. He is also a board member with FIND Foundation and Illumina Inc.

"We are very pleased that Dr Moeller is joining our supervisory board,” says Benedikt Timmerman, founder and CEO of Genticel. “His wealth of expertise in the pharmaceutical industry represents a considerable asset for Genticel, especially at a key moment in our development. We are launching the phase II clinical trial of our lead product, ProCervix, in Europe - so it is a priority for Genticel to forge close ties with major pharmaceutical industry players. Gerry's experience in this industry and his strategic advice will be invaluable in this."

"The results of the phase I trial of ProCervix are very encouraging. It is the first vaccine to meet the medical needs of over 90 million women infected with HPV16 and/or 18," says Dr Gerald Moeller. "I am delighted to help Genticel reap the benefits of such promising projects."

The supervisory board at Genticel is chaired by Professor Thierry Hercend. The membership comprises Ludovic de Meeus d'Argenteuil, co-founder of Genticel; Alain Munoz, representing Kurma Life Sciences; Raphael Wisniewski, director of investment at Edmond de Rothschild Investment Partners (EdRIP); Olivier Martinez, director of investment, life sciences, BPI France; Alexandre Flageul, partner at Amundi Private Equity Funds; and Dr Didier Hoch, an independent industry member.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genticel Announces Positive Preclinical Proof of Concept Results of GTL002
Based on Company's versatile Vaxiclase platform.
Tuesday, June 02, 2015
Genticel Completes Procervix Phase II Study Enrollment Ahead of Schedule
A total of 239 subjects infected with HPV 16 and/or 18 enrolled at 39 clinical centers throughout Europe for RHEIA-VAC study of ProCervix.
Saturday, November 15, 2014
Genticel: Business Update - Third Quarter 2014
Net cash and equivalents of €35.2 million as of September 30, 2014.
Tuesday, November 04, 2014
Mary Tanner Appointed to Genticel’s Supervisory Board
Ms. Tanner appointed as independently-acting member and as Audit Committee chairman.
Tuesday, October 07, 2014
Genticel’s Phase II Study with ProCervix Passes the Halfway Mark for Patient Recruitment
The trial is proceeding as planned, after first DSMB (Data and Safety Monitoring Board) review.
Friday, July 18, 2014
Genticel Launches its Phase II Trial in Women Infected with High-Risk HPV
The appointment of Dr. Sophie Olivier as chief medical officer completes the Genticel team to run the Phase II trial across Europe.
Thursday, March 06, 2014
Genticel Secures EUR 18.2 Million (USD 23.7 million) in Capital Funding
Dr. Rainer Strohmenger joins the supervisory board of Genticel.
Friday, April 26, 2013
Genticel Announces Positive Data from Phase I Trial in HPV Infected Women
First ever trial to recruit HPV infected women with no cervical lesions.
Tuesday, April 16, 2013
Genticel Completed Recruitment for its Phase Ib Vaccine Trial in HPV Infected Women
Company expects the final results before the end of the second quarter 2012.
Wednesday, February 22, 2012
Genticel Completes Patient Recruitment for its Phase I Trial with ProCervix
Company expects to complete its full Phase I Program in the first half of 2012.
Thursday, October 20, 2011
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
BGI Sequences Gingko Tree, Revealing Large, Highly Repetitive Genome
Researchers at BGI have sequenced the more than 10-gigabase ginkgo genome to find a high number of repetitive sequences as well as a number of gene clusters that appear to be involved in defense mechanisms.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!